- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
The Woodlands Today
By the People, for the People
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
Autonomix's precision nerve-targeted treatment technology to be featured at leading cardiovascular conference
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
Autonomix Medical, Inc., a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced that its presentation titled 'Illuminating The Nervous System With Transvascular Precision-guided Technology' has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.
Why it matters
Selection for the CRT Best Innovation Competition highlights the potential of Autonomix's precision-guided, transvascular approach to interrogating and treating the nervous system, which could provide physicians with unprecedented insight into peripheral nerve signaling and enable new treatments for conditions like pancreatic cancer pain.
The details
Autonomix's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution.
- The presentation will be delivered by Autonomix's Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET.
- CRT 2026 will take place in March 2026.
The players
Autonomix Medical, Inc.
A medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.
Brad Hauser
Chief Executive Officer of Autonomix Medical, Inc.
What they’re saying
“Being selected for CRT's Best Innovation Competition is a strong validation of our precision-guided, transvascular approach to interrogating and treating the nervous system. Our technology is designed to provide physicians with unprecedented insight into peripheral nerve signaling.”
— Brad Hauser, Chief Executive Officer (Globe Newswire)
What’s next
Autonomix's technology is investigational and has not yet been cleared for marketing in the United States. The company will continue to develop and test its precision nerve-targeted treatment technology, with the goal of bringing it to market to help address conditions like pancreatic cancer pain.
The takeaway
Autonomix's selection for the CRT Best Innovation Competition highlights the potential of its innovative approach to diagnosing and treating diseases involving the nervous system, which could lead to new and more effective treatments for debilitating conditions like pancreatic cancer pain.
